Apimeds Pharmaceuticals US (APUS) Net Cash Flow (2024 - 2025)
Apimeds Pharmaceuticals US (APUS) posted Net Cash Flow of -$5.3 million for Q4 2025, down 205.94% on a QoQ basis from -$1.7 million in Q3 2025, and down 23043.98% year-over-year from N/an in Q4 2024.
Apimeds Pharmaceuticals US (APUS) Net Cash Flow (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US's Net Cash Flow history runs 2 years deep, the most recent figure standing at -$5.3 million for Q4 2025.
- Quarterly Net Cash Flow fell 23043.98% year-over-year to -$5.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.6 million (up 424.75% YoY) and the FY2025 annual result came in at $1.6 million, up 501.25% from the prior year.
- Net Cash Flow was -$5.3 million for Q4 2025 at Apimeds Pharmaceuticals US, down from -$1.7 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $8.5 million in Q2 2025 and bottomed at -$5.3 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 202.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -526.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 711.50 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -277.40 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 461.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -446.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -112.00 Mn |
| 10 | Apimeds Pharmaceuticals US | 8.17 Mn | 8.17 Mn | - | -5.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.35 Mn |
| Dec 31, 2025 | -5.35 Mn |
| Sep 30, 2025 | -1.75 Mn |
| Sep 30, 2025 | -1.75 Mn |
| Jun 30, 2025 | 8.50 Mn |
| Jun 30, 2025 | 8.50 Mn |
| Mar 31, 2025 | 246,887.00 |
| Mar 31, 2025 | 246,887.00 |
| Dec 31, 2024 | -23,116.00 |
| Dec 31, 2024 | -23,116.00 |
| Sep 30, 2024 | -36,755.00 |
| Sep 30, 2024 | -36,755.00 |
| Jun 30, 2024 | -184,055.00 |
| Jun 30, 2024 | -184,055.00 |
| Mar 31, 2024 | -263,100.00 |
| Mar 31, 2024 | -263,100.00 |